ProBioGen AG, a service and technology provider for complex therapeutic antibodies and glycoproteins, signed a Master Service Agreement with Heidelberg Pharma for the antibodies used in two of its pipeline Antibody Targeted Amanitin Conjugate (ATAC) molecules.

Under the agreement, ProBioGen is conducting the full service package from cell line development using its CHO.RiGHT cell line expression platform and DirectedLuck Transposase system for the generation of high titer producer clones, through process development and GMP manufacturing of the mAb intermediates of Heidelberg Pharma’s ATAC molecules for cancer indications.

“We are delighted to welcome Heidelberg Pharma, proven experts for the innovative active ingredient Amanitin and ADCs, to our list of international customers,” said Dr. Lutz Hilbrich, Chief Executive Officer of ProBioGen. “Our longstanding, more than 25 years of experience and positive track record paired with always trend setting new technologies, convinced Heidelberg Pharma to work together with ProBioGen on two of their product candidates to advance them into clinical studies with the ultimate aim to serve and help patients in need. We are strongly committed to our customers and their needs, and in line with demand we are looking forward to continuous collaborations based on already increased and further increasing production capacity.”

“Working with the right partner is a critical element in developing a compelling product candidate,” said Dr. Jan Schmidt-Brand, Heidelberg Pharma’s Chief Executive Officer. “Thus we are excited to work with ProBioGen as they have both, the technical expertise and a very committed team. ProBioGen is well known in the community to provide highest quality in proven timelines. Heidelberg Pharma’s commitment to developing life-changing therapies for patients is a perfect match for their focus on the client’s needs.”